表紙
市場調查報告書

高血壓治療藥的全球市場 (2019-2029年):ARB、ACE抑制劑(血管收縮素轉換酵素抑制劑)、β- 阻斷劑、CCB、利尿劑、FDC

Global Hypertension Drugs Market 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs)

出版商 Visiongain Ltd 商品編碼 910376
出版日期 內容資訊 英文 145 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
高血壓治療藥的全球市場 (2019-2029年):ARB、ACE抑制劑(血管收縮素轉換酵素抑制劑)、β- 阻斷劑、CCB、利尿劑、FDC Global Hypertension Drugs Market 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs)
出版日期: 2019年07月31日內容資訊: 英文 145 Pages
簡介

高血壓治療藥的市場在預測期間內預計將以-2.3%的年複合成長率 (CAGR) 發展,從2018年的247億美元,縮小到2029年193億美元的規模。

本報告提供全球高血壓治療藥的市場調查,高血壓及高血壓治療藥概要,對市場成長的各種影響因素及市場機會分析,各藥物類型、地區/主要國家趨勢與市場規模的變化與預測,肺動脈高血壓 (PAH) 部門的詳細分析,開發平台趨勢,主要企業簡介等資訊彙整。

第1章 報告概要

第2章 簡介:高血壓治療藥市場

  • 高血壓:概要
  • 原因
  • 流行病學
  • 其他疾病的關聯性
  • 高血壓治療
  • 治療標的、主要的治療藥

第3章 市場概要

  • 市場定義及分類
  • 市場規模、成長預測
  • 市場動態
    • 成長推動因素
    • 阻礙成長要素
    • 市場機會
  • 產業分析
    • 波特的五力分析
  • 價值鏈分析
  • 市場機會分析

第4章 高血壓治療藥市場分析、預測:各類型

  • 簡介
  • β- 阻斷劑
  • ACE抑制劑
  • CCB
  • ARB
  • 利尿劑
  • FDC
  • 高血壓患者的展望

第5章 肺動脈高血壓 (PAH) 部門分析、預測

第6章 高血壓治療藥市場分析、預測:各地區、主要國家

  • 主要國家市場成果、預測
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 日本
  • 中國
  • 印度
  • 亞洲的其他地區
  • 俄羅斯
  • 巴西
  • 南非
  • 其他地區

第7章 主要企業

  • Actelion
  • Johnson & Johnson Company
  • AstraZeneca
  • Sanofi Aventis
  • 第一三共
  • Novartis
  • Pfizer
  • Merck & Co.
  • Boehringer Ingelheim GmbH
  • United Therapeutics

第8章 開發平台開發

第9章 總論、建議

第10章 主要調查結果

目錄
Product Code: PHA0457

The global hypertension drugs market is estimated to have reached $24.7bn in 2018 and is expected to reach the market value of $19.3bn by 2029 with a CAGR of -2.3% from 2019 to 2029.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 146-page report you will receive 118 charts - all unavailable elsewhere.

The 146-page report provides clear detailed insight into the hypertension drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Hypertension Drugs Market forecasts from 2019-2029
  • Global Pulmonary Arterial Hypertension (PAH) Market forecasts from 2019-2029
  • Revenue forecasts for the Hypertension Drugs by Class of Drug from 2019-2029:
  • Angiotensin II Receptor Blockers (ARBs): further broken down into revenue forecast of Atacand, Avapro, Diovan, Cozaar, Benicar, Entresto, Micardis, Azilva, Candesartan
  • Angiotensin-converting Enzyme (ACE) Inhibitor: further broken down into revenue forecast of Tritace
  • Beta-Blockers: further broken down into revenue forecast of Seloken/Toprol-XL, Coreg CR, Concor
  • Calcium Channel Blockers (CCBs): further broken down into revenue forecast of Norvasc, Plendil, Adalat, Amlodin
  • Diuretics
  • Fixed-dose Combinations (FDC): further broken down into revenue forecast of Azor, Tribenzor, Exforge, Tekturna HCT, others

Revenue forecasts for the leading PAH drugs from 2019-2029:

  • Tacleer
  • Uptravi
  • Opsumit
  • Letairis
  • Adcirca
  • Revatio
  • Adempas
  • Veletri
  • Oremitram
  • Tyvaso
  • Remodulin

Revenue forecasts for the Hypertension Drugs by Regional and National Market from 2019-2029:

  • U.S.
  • Canada
  • Mexico
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
  • Russia
  • Japan
  • China
  • India
  • Rest of Asia
  • Brazil
  • South Africa
  • Rest of the World

Profiles and discussion on the leading companies of the hypertension drugs market:

  • Actelion
  • AstraZeneca
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo
  • Johnson & Johnson Company
  • Merck & Co.
  • Novartis
  • Pfizer
  • Sanofi Aventis
  • United Therapeutics

Analysis of the Drivers, Restraints, Opportunities and Porter's Five Forces analysis of the global hypertension drugs market

Key Questions Answered by this Report:

  • How is the Hypertension Drugs market evolving?
  • What is driving and restraining the Hypertension Drugs market dynamics?
  • How will each of the submarkets grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each of the Hypertension Drugs submarkets develop from 2019 to 2029?
  • What will be the main driver for the overall market from 2019-2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • How will the market shares of the national markets change by 2029 and which geographical region will lead the market in 2029?
  • Who are the leading players and what are their prospects over the forecast period?
  • How will the industry sector evolve during the period between 2019 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the Global Hypertension Drugs Market. You find data, trends and predictions.

Buy our report today Global Hypertension Drugs Market 2019-2029: Angiotensin II Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Beta Blockers, Calcium Channel Blockers (CCBs), Diuretics, Fixed-dose Combinations (FDCs).

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Hypertension Drugs Market Overview
  • 1.2 Overview of Findings
  • 1.3 Global Hypertension Drugs Market Segmentation, 2019
  • 1.4 Structure of the Report
  • 1.5 How This Report Delivers
  • 1.6 Key Questions Answered by This Analytical Report
  • 1.7 Who is This Report For?
  • 1.8 Methodology
  • 1.9 Frequently Asked Questions (FAQ)
  • 1.10 Associated Visiongain Reports
  • 1.11 About Visiongain

2. Introduction to the Hypertension Drugs Market

  • 2.1 An Overview of Hypertension
  • 2.2 Causes of Hypertension
  • 2.3 Primary Hypertension
  • 2.4 Secondary Hypertension
  • 2.5 Pulmonary Hypertension
  • 2.6 Epidemiology of Hypertension
  • 2.7 Links with Other Disorders
  • 2.8 Treatment of Hypertension
  • 2.9 Treatment Targets and the Selection of Drugs

3. Hypertension Drugs Market Overview, 2018

  • 3.1 Market Definition and Segments covered:
  • 3.2 Global Hypertension Drugs Market Segmentation
  • 3.3 Market Size and Growth Prospects
  • 3.4 Hypertension Drugs Market Dynamics (Drivers & Restraints)
    • 3.4.1 Drivers
      • 3.4.1.1 Rising Prevalence of Hypertension to boost the market growth
      • 3.4.1.2 Rising complications of untreated blood pressure
      • 3.4.1.3 Growing government and private initiatives to prevent and treat hypertension
    • 3.4.2 Restraints
      • 3.4.2.1 Tough generic competition due to patent expiry
      • 3.4.2.2 Rising non-pharmacological treatment
    • 3.4.3 Opportunities
      • 3.4.3.1 Introduction of novel approaches for the treatment of hypertension
  • 3.5 Hypertension Market Industry Analysis
    • 3.5.1 Porter's Five Force Analysis
      • 3.5.1.1 Rivalry among Competitors [High]
      • 3.5.1.2 Threat of New Entrants [Low]
      • 3.5.1.3 Power of Suppliers [High]
      • 3.5.1.4 Power of Buyers [Medium]
      • 3.5.1.5 Threat of Substitutes [Low]
  • 3.6 Value Chain Analysis
    • 3.6.1 Manufacturer of medicine:
    • 3.6.2 Wholesalers:
    • 3.6.3 Pharmacy:
    • 3.6.4 Health Plans and Pharmacy Benefit Managers (PBMs):
  • 3.7 Opportunity Analysis
  • 3.7.1 PAH (Pulmonary Arterial Hypertension Market)

4. Hypertension Drugs Market by Types, 2019-2029

  • 4.1 Introduction
  • 4.2 Beta Blockers
  • 4.3 Angiotensin Converting Enzyme (ACE) Inhibitors
  • 4.4 Calcium Channel Blockers (CCBs)
  • 4.5 Angiotensin II Receptor Blocker (ARBs)
  • 4.6 Diuretics
  • 4.7 Fixed Dose Combination (FDCs)
  • 4.8 Prospects for Hypertension Patients
  • 5. Pulmonary Arterial Hypertension (PAH), 2019-2029
  • 6. The Leading National Hypertension Drugs Market, 2019-2029
  • 6.1 The Leading National Hypertension Drugs Market, 2018
  • 6.2 The Leading National Hypertension Drugs Market, 2029
  • 6.3 Leading National Hypertension Drugs Market Forecast, 2019-2029
  • 6.4 The US Hypertension Drugs Market Forecast, 2019-2029
  • 6.5 The Canadian Hypertension Drugs Market Forecast, 2019-2029
  • 6.6 The Mexican Hypertension Drugs Market Forecast, 2019-2029
  • 6.7 The European Hypertension Drugs Market, 2019-2029
    • 6.7.1 EU Hypertension Drugs Market Forecast, 2019-2029
      • 6.7.1.1 The German Hypertension Drugs Market Forecast 2019-2029
      • 6.7.1.2 The French Hypertension Drugs Market Forecast 2019-2029
      • 6.7.1.3 The UK Hypertension Drugs Market Forecast, 2019-2029
      • 6.7.1.4 The Italian Hypertension Drugs Market Forecast, 2019-2029
      • 6.7.1.5 The Spanish Hypertension Drugs Market Forecast, 2019-2029
      • 6.7.1.6 Rest of Europe (RoE) Hypertension Drugs Market Forecast, 2019-2029
  • 6.8 Japanese Hypertension Drugs Market Forecast, 2019-2029
  • 6.9 The Chinese Hypertension Drugs Market Forecast, 2019-2029
  • 6.10 The Indian Hypertension Drugs Market Forecast, 2019-2029
  • 6.11 The Rest of Asia (ROA) Hypertension Drugs Market Forecast, 2019-2029
  • 6.12 Russian Hypertension Drugs Market Forecast, 2019-2029
  • 6.13 The Brazilian Hypertension Drugs Market Forecast, 2019-2029
  • 6.14 South Africa Hypertension Drugs Market Forecast, 2019-2029
  • 6.15 RoW Hypertension Drugs Market Forecast, 2019-2029

7. Leading Companies in Hypertension Drugs Market 2019-2029

  • 7.1 Actelion (now a Johnson & Johnson company)
    • 7.1.1 Financial Performance
    • 7.1.2 Product Sales Performance
    • 7.1.3 PAH Product Sales Performance
    • 7.1.4 Merger and Acquisition
  • 7.2 Johnson & Johnson Company
    • 7.2.1 Merger and Acquisition
    • 7.2.2 New Drug Development for Resistant Hypertension
  • 7.3 AstraZeneca
    • 7.3.1 Financial Performance
    • 7.3.2 Financial Performance by Segments
    • 7.3.3 Major Cardiovascular Products
    • 7.3.4 Anti-Hypertension Products and Patent Status
    • 7.3.5 Anti-Hypertension Products Sales by Region
    • 7.3.6 Recent Developments
  • 7.4 Sanofi Aventis
    • 7.4.1 Financial Performance
      • 7.4.1.1 Financial Performance by Segments
  • 7.5 Daiichi Sankyo
    • 7.5.1 Financial Performance
    • 7.5.2 Products
  • 7.6 Novartis
    • 7.6.1 Financial Performance by Business Segments
    • 7.6.2 Products
    • 7.6.3 Pipeline Products
  • 7.7 Pfizer
    • 7.7.1 Pfizer Financial Performance, 2015-2017
    • 7.7.2 Products- PAH
  • 7.8 Merck & Co.
    • 7.8.1 Merck &Co. Financial Performance, 2015-2017
  • 7.9 Boehringer Ingelheim GmbH
    • 7.9.1 Financial Performance, 2016-2017
  • 7.10 United Therapeutics
    • 7.10.1 Financial Performance, 2015-2017
    • 7.10.2 Financial Performance by Geography, 2015-2017

8. Pipeline Developments in Hypertension

9. Conclusions & Recommendations

10. Key Findings

  • 10.1 Market Snapshot: World Hypertension Drugs Market (2019 & 2029)
  • 10.2 Market Drivers & Restraints

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Categories of Blood Pressure in Adults
  • Table 4.1 Global Beta Blockers Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.2 Leading Beta Blockers to treat Hypertension
  • Table 4.3 The Beta Blockers Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.4 The Beta Blockers Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.5 The ACE Inhibitors Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.6 Leading ACE Inhibitors to treat Hypertension
  • Table 4.7 The ACE Inhibitor Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.8 The ACE Market Forecast by Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.9 The CCBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.10 Leading Calcium Channel Blockers to treat Hypertension
  • Table 4.11 The CCBs Market Forecast by Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.12 The CCBs Generics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.13 The ARBs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.14 The ARBs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.15 Leading ARBs to treat Hypertension
  • Table 4.16 The ARBs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.17 The Diuretics Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.18 The FDCS Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.19 The FDCs Market Leading Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 4.20 Leading FDCs to treat Hypertension
  • Table 4.21 The FDCs Market Forecast of Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 5.1 The PAH Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 5.2 The PAH Market Forecast for Leading Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 5.3 The PAH Market Forecast for Generic Drugs: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.1: The Hypertension Drugs Market by Country: Revenue ($bn), and Market Share (%), 2018
  • Table: 6.2 The Hypertension Drugs Market by Country: Revenue ($bn), 2029
  • Table 6.3 The Leading National Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.4 The US Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.5 Canada Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.6 Mexico Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.7 The European Hypertension Drugs Market by Country: Revenue ($bn) and Market Share (%), 2018
  • Table 6.8 EU Hypertension Drugs Market by Country Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.9 Germany Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and
  • Table: 6.10 France Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.11. UK Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.12 Italy Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.13 Spain Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.14 Rest of Europe (RoE) Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.15 Japan Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.16 China Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.17 India Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.18 RoA Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.19 Russia Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.20 Brazil Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.21 South Africa Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 6.22 RoW Hypertension Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2019-2029
  • Table 7.1 Actelion Revenue: Product Sales ($mn), Core R&D ($mn) and Operating Income ($mn), 2014-2016
  • Table 7.2 Actelion Revenue, Product Sales ($mn), 2015-2016
  • Table 7.3 Opsumit Revenue, Product Sales ($mn) by Region, 2015-2016
  • Table 7.4 Uptravi Revenue, Product Sales (USD mn), By Region, 2015-2016
  • Table 7.5 Veletri Revenue, Product Sales ($mn), By Region, 2015-2016
  • Table 7.6 Ventavis Revenue, Product Sales ($mn), By Region, 2015-2016
  • Table 7.7 J&J Pharmaceutical: Revenue ($bn), Revenue Share (%) by Segment, 2016 and 2017
  • Table 7.8 AstraZeneca Net Sales by Product Category, ($mn),2015-2017
  • Table 7.9 AstraZeneca's Anti-Hypertension Drugs Portfolio and Patent Status
  • Table 7.10 AstraZeneca's Anti-Hypertension Products Sales by Region, ($mn), 2015-2017
  • Table 7.11 Daiichi Sankyo Antihypertension Products by Business Units
  • Table 7.12 Novartis Pharmaceuticals by Division: Revenue ($mn), 2017
  • Table 7.13 Established Medicine by Division: Revenue ($mn), 2017 (Y-O-Y change in USD %)
  • Table 7.14 Novartis Pipeline Products for Hypertension and Clinical Trial Phase
  • Table 7.15 Pfizer by Division: Revenue ($mn),2015- 2017
  • Table 7.16 Pfizer by Geography: Revenue ($mn), 2015- 2017
  • Table 7.17 Pfizer for PAH: Revenue ($mn), 2015- 2017
  • Table 7.18 Merck & Co.: Revenue by Segments ($mn), 2015-2017
  • Table 7.19 Merck & Co.: Revenue, By Anti-Hypertension Products ($mn), 2015- 2017
  • Table 7.20 Merck & Co.: Cozaar Revenue by Geography ($mn), 2015- 2017
  • Table 7.21 Merck & Co.: Adempas Revenue by Geography ($mn),2015- 2017
  • Table 7.22 Boehringer Ingelheim: Revenue by Segments ($mn), 2015- 2017
  • Table 7.23 Boehringer Ingelheim: Revenue by Segments ($mn),2016- 2017
  • Table 7.24 Boehringer Ingelheim: Anti-Hypertension Revenue by Products ($mn), 2016- 2017
  • Table 7.25 United Therapeutics PAH Revenue by Products ($mn),2016- 2017
  • Table 7.26 United Therapeutics Revenue by Geography ($mn), 2015- 2017Table 10.1 Market Snapshot: World Ophthalmic devices Market (2019 & 2029)

List of Figures

  • Figure 1.1 Hypertension Drugs Market: Overview of Submarkets, 2019
  • Figure 3.1: Global Hypertension Drugs: Overview of Submarkets and Drugs /Classes, 2019
  • Figure 3.2: Global Hypertension Drugs Market: Drivers & Restraints, 2019
  • Figure 3.3: Porter's Five Forces Analysis of the Hypertension Drugs Market
  • Figure 3.4: Value Chain Analysis Hypertension Drugs Market, 2019
  • Figure 4.1 Hypertension Drugs Market by Type of Drugs: Market Share (%), 2018
  • Figure 6.1 The Hypertension Drugs Market by Region: Revenue ($bn), 2018
  • Figure 6.2: The Hypertension Drugs Market by Region: Market Share (%), 2018
  • Figure: 6.3 The Hypertension Drugs Market by Country: Revenue ($bn), (%), 2029
  • Figure 6.4 The Hypertension Drugs Market by Country: Market Share (%), 2029
  • Figure: 6.5 The US Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.6 Canada Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.7 Mexico Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.8 EU Hypertension Drugs Market by Country: Revenue ($bn), 2018
  • Figure 6.9 EU Hypertension Drugs Market by Country: Market Share (%), 2018
  • Figure 6.10 EU Hypertension Drugs Market Forecast by Country: Revenue ($bn) and AGR (%), 2019-2029 CAGR (%), 2019-2029
  • Figure 6.11 Germany Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.12 France Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.13 UK Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.14 Italy Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.15 Spain Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.16 The ROE Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.17 Japan Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.18 China Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.19 India Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.20 RoA Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.21 The Russia Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.22 Brazil Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.23 South Africa Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 6.24 RoW Hypertension Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029
  • Figure 7.1 AstraZeneca Financial Performance ($mn), 2015-2017
  • Figure 7.2 Sanofi Aventis Net Sales ($mn),2015-2017
  • Figure 7.3 Sanofi Aventis Net Sales by Segments ($mn),2015-2017
  • Figure 7.4 Daiichi Sankyo Net Revenues: ($mn), (2015-2017)
  • Figure 7.5 Novartis Revenue ($bn), 2017
  • Figure 7.6 Novartis Pharmaceutical by Business Segment: Revenue Share (%),2017
  • Figure 7.7 Pfizer Revenue ($mn): 2015- 2017
  • Figure 7.8 Merck & Co. Revenue ($mn): 2015- 2017
  • Figure 7.9 Boehringer Ingelheim & Co. Revenue ($mn): 2016- 2017
  • Figure 7.10 United Therapeutics Revenue ($mn): 2015- 2017
  • Figure 8.1. Pulmonary Hypertension Clinical Trials
  • Figure 8.2. Essential Hypertension Clinical Trials

COMPANIES LISTED:

  • Actelion Ltd.
  • Alcon
  • AstraZeneca
  • Aventis
  • Bayer Inc.
  • Boehringer Ingelheim
  • CMS
  • Daiichi Sankyo, Inc.
  • Elf Aquitaine
  • Eli Lilly
  • GlaxoSmithKline
  • Hoechst and Rhone -Poulenc
  • Innovative Medicines
  • Ivax
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • Labaz
  • Lek Pharmaceuticals
  • Merck & Co.
  • Mylan Pharma
  • Novartis
  • Pfizer
  • R&D NewCo
  • Sanis Health, Inc.
  • Sankyo
  • Sanofi-Aventis
  • Sanofi-Synthelabo
  • Takeda Pharmaceuticals
  • Teva Pharmaceuticals
  • United Therapeutics
  • Valeant Pharmaceuticals
  • Zeneca Group PLC

List of Organisations Mentioned in the Report:

  • American Heart Association
  • Bureau of Pharma PSUs of India
  • The National Heart, Lung and Blood Institute
  • US National Institute of Health
  • World Health Organization
  • World Heart Federation
Back to Top